How Vaccines Are Regulated
From preclinical research to post-market surveillance — understanding the regulatory journey.
Vaccine regulation is a complex, multi-stage process designed to ensure safety, efficacy, and quality before a vaccine reaches the public — and continues long after. This section maps the complete regulatory journey, explaining the roles of key agencies, the standards they enforce, and how vaccines are monitored throughout their lifecycle.
The Vaccine Development Pipeline
Before a vaccine is approved, it must navigate a rigorous development and evaluation process:
- Preclinical: Laboratory and animal studies to establish biological plausibility and safety
- Phase I: First human trials — safety and immunogenicity in small groups (20-100)
- Phase II: Expanded safety and dosing studies (hundreds of participants)
- Phase III: Large-scale efficacy and safety trials (thousands to tens of thousands)
- Regulatory Review: Comprehensive data review by FDA/EMA/WHO
- Post-Market Surveillance: Ongoing safety monitoring throughout vaccine use
Key Regulatory Agencies
FDA (US)
Center for Biologics Evaluation and Research (CBER) oversees vaccine approval in the United States.
Learn more →EMA (EU)
European Medicines Agency coordinates vaccine evaluation across 27 EU member states.
Learn more →WHO
World Health Organization prequalifies vaccines for global procurement and distribution.
Learn more →Approval Pathways
- Full Licensure (BLA): Complete review of Phase I-III data, manufacturing, labeling
- Emergency Use Authorization (EUA): Expedited review during public health emergencies
- WHO Prequalification: Required for UNICEF/Gavi procurement in low-income countries
Post-Market Surveillance
Regulatory oversight doesn't end with approval. Manufacturers and regulators continuously monitor vaccine safety:
- Adverse event reporting systems (VAERS, Yellow Card, EudraVigilance)
- Active surveillance networks (VSD, BEST)
- Periodic safety update reports from manufacturers
- Post-marketing studies required by regulators